Antagonism of vascular endothelial growth factor for macular edema caused by retinal vein occlusions: Two-year outcomes

Peter A. Campochiaro, Gulnar Hafiz, Roomasa Channa, Syed M. Shah, Quan Dong Nguyen, Howard Ying, Diana V. Do, Ingrid Zimmer-Galler, Sharon D. Solomon, Jennifer U. Sung, Beena Syed

Research output: Contribution to journalArticle

58 Scopus citations

Abstract

Purpose: To determine the long-term effects of intraocular antagonism of vascular endothelial growth factor (VEGF) in patients with macular edema caused by retinal vein occlusions (RVOs). Design: Prospective randomized trial. Participants: Twenty patients with macular edema caused by branch RVOs (BRVOs) and 20 patients with central RVOs (CRVOs). Methods: After the month 3 primary end point, patients were seen every 2 months and received injections of an anti-VEGF agent as needed for recurrent edema. Main Outcome Measures: Mean change from baseline best-corrected visual acuity (BCVA) at month 24 with assessment of other parameters of visual function and center subfield thickness (foveal thickness [FTH]). Results: For 17 patients with BRVO who completed 2 years of follow-up, the mean improvement from baseline in BCVA at month 24 was 17.8 letters compared with 15.6 letters at month 3. Improvement by at least 6, 3, or 2 lines occurred in 18%, 59%, and 76% of patients, respectively. The Snellen equivalent BCVA at month 24 was 20/40 or better in 10 patients. With an average of 2 injections of ranibizumab during year 2, the mean FTH at month 24 was 245.8 μm compared with 217.1 μm at month 3 and 481.5 μm at baseline. For 14 patients with CRVO who completed 2 years of follow-up, the mean improvement in BCVA at month 24 was 8.5 letters compared with 12.0 letters at month 3. Improvement by at least 6, 3, or 2 lines occurred in 14%, 21%, and 43% of patients, respectively. The Snellen equivalent BCVA at month 24 was 20/40 or better in 4 patients. With an average of 3.5 injections of ranibizumab in year 2, mean FTH at month 24 was 338 μm compared with 278 μm at month 3 and 533 μm at baseline. Duration of RVO >1 year at study entry and nonperfusion of perifoveal capillaries for 360 degrees correlated with reduced visual outcomes. Conclusions: Antagonism of VEGF provides substantial long-term benefit to patients with macular edema caused by RVO, but frequent injections are required in some patients with BRVO and most patients with CRVO. Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references.

Original languageEnglish (US)
Pages (from-to)2387-2394.e5
JournalOphthalmology
Volume117
Issue number12
DOIs
StatePublished - Dec 2010

ASJC Scopus subject areas

  • Ophthalmology

Fingerprint Dive into the research topics of 'Antagonism of vascular endothelial growth factor for macular edema caused by retinal vein occlusions: Two-year outcomes'. Together they form a unique fingerprint.

  • Cite this

    Campochiaro, P. A., Hafiz, G., Channa, R., Shah, S. M., Nguyen, Q. D., Ying, H., Do, D. V., Zimmer-Galler, I., Solomon, S. D., Sung, J. U., & Syed, B. (2010). Antagonism of vascular endothelial growth factor for macular edema caused by retinal vein occlusions: Two-year outcomes. Ophthalmology, 117(12), 2387-2394.e5. https://doi.org/10.1016/j.ophtha.2010.03.060